CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2022 Earnings Call Transcript

Yehiel Tal: Yes, thank you. So, in closing, I want to reiterate our upcoming goals for 2023: continue to advance development of paradigm shifting regenerative, dermal and soft tissue fillers with AbbVie, expecting first milestone achievement in 2023, initiate study in large animals with commercial sized breast implants to generate additional safety data in support of commercialization, advanced development of the Gut-on-a-Chip tissue model for drug discovery and personalized treatment of ulcerative colitis. We continue to expand our commercial portfolio of rhCollagen-based BioInks and the last one is form new collaborations with industry leaders to co-develop therapeutics and medical applications. I would like to thank everyone for joining us on our first conference call.

I want to reiterate that we are committed to becoming the leaders in regenerative medicine and supporting more sustainable ecosystems that benefits all stakeholders, including patients, our shareholders, our employees and providing innovation to the life science industry. As mentioned, our vision is to enable a world with unlimited organ supply, regenerative tissue products and novel drugs and diagnostics that do not rely on animal trials. We are targeting substantial and attractive markets to do this, and we look forward to a promising and exciting year ahead. Thank you.

Operator: Thank you. This does conclude today’s teleconference. We appreciate your participation. You may disconnect at this time. Enjoy the rest of your day.